|
시장보고서
상품코드
1873362
세계의 화농성 한선염 치료 시장 : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)Hidradenitis Suppurativa Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 |
||||||
QYResearch
세계의 화농성 한선염 치료 시장 규모는 2024년에 6억 9,800만 달러로 추정되며, 2025년부터 2031년까지 예측 기간 동안 CAGR 4.2%로 성장하여 2031년까지 9억 2,700만 달러로 확대될 것으로 예측됩니다.
한선염(HS)은 피부에 농양과 흉터를 유발하는 고통스러운 만성 피부질환입니다. 정확한 원인은 알 수 없으나 땀샘이 존재하는 모낭 주변, 주로 사타구니, 엉덩이, 유방, 겨드랑이, 겨드랑이에 발생합니다. HS의 근본적인 치료법은 없지만, 치료와 생활습관 개선을 통해 증상 완화 및 발작 빈도를 줄일 수 있습니다.
한선염(HS) 치료 시장은 주로 이 만성적이고 인지도가 낮은 피부 질환에 대한 인식과 진단율의 향상에 의해 주도되고 있습니다. 더 많은 피부과 전문의와 일차 의료 서비스 제공자가 HS의 초기 증상에 대해 더 많이 알게 됨에 따라 조기 진단과 개입이 더욱 보편화되고 있습니다. 또한, TNF-α 억제제(예 : 아달리무맙)와 같은 첨단 생물학적 제제의 보급으로 HS의 관리는 대증요법에서 표적 질환 조절 치료로 변화하고 있습니다. 환자 지원 활동의 활성화, 신흥 시장에서의 의료 접근성 향상, 피부과 영역의 연구개발에 대한 지속적인 투자가 시장 성장을 더욱 촉진하고 있습니다.
이러한 발전에도 불구하고, HS 치료 시장은 몇 가지 도전에 직면해 있습니다. 가장 큰 장벽 중 하나는 특히 중저소득 국가에서 생물학적 제제의 높은 비용과 제한된 보험 적용입니다. 또한, 중등도 및 중증 환자들에 대한 기존 치료법의 효과의 한계와 근본적인 치료법의 부족은 환자들의 불만과 치료 중단의 원인이 되고 있습니다. 진단 지연, 사회적 편견, 새로운 치료법에 대한 임상시험 데이터 부족도 시장 확대를 제한하고 제약회사와 의료 서비스 제공자에게 지속적인 도전이 되고 있습니다.
화농성 한선염 치료의 분류에는 약물, 수술, 기타가 포함되며, 2019년 약물의 비율은 약 76%를 기록할 것으로 예상됩니다. 화농성 한선염 치료는 병원, 임상 및 기타 분야에서 널리 사용됩니다. 화농성 한선염 치료에서 가장 큰 비중을 차지하는 곳은 병원이며, 2024년에는 53.53%의 비중을 차지할 것으로 예상됩니다. 유럽은 가장 큰 소비지이며, 2024년 소비 시장 점유율은 47.76%를 차지할 것입니다. 아시아태평양은 유럽에 이어 두 번째로 큰 소비지이며, 소비 시장 점유율은 23.97%를 기록할 것으로 예상됩니다. 시장 경쟁이 심화되고 있으며, AbbVie, Merck, Pfizer, AstraZeneca, GlaxoSmithKline 등이 업계를 선도하고 있습니다.
이 보고서는 화농성 한선염 치료 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위에 초점을 맞추고 지역/국가, 유형 및 용도별 분석을 종합적으로 제시하는 것을 목표로 합니다.
화농성 한선염 치료 시장의 규모, 추정 및 예측은 2024년을 기준 연도로 하여 2020년에서 2031년까지의 과거 데이터와 예측 데이터를 포함하는 매출 수익으로 제시되었습니다. 정량적, 정성적 분석을 통해 화농성 한선염 치료 관련 사업 전략 및 성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 자사 포지셔닝 분석, 정보에 입각한 사업적 판단을 내리는데 도움이 될 것입니다.
시장 세분화
기업별
- AbbVie
- Merck
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Perrigo
- Sun Pharma
- Almirall
- Bausch Health
- Johnson & Johnson
- UCB Pharma
- Amgen
- NCPC
유형별 부문
- 의약품
- 외과수술
- 기타
용도별 부문
- 병원
- 진료소
- 기타
지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 한국
- 동남아시아
- 인도
- 호주
- 기타 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 네덜란드
- 북유럽 국가
- 기타 유럽
- 라틴아메리카
- 멕시코
- 브라질
- 기타 라틴아메리카
- 중동 및 아프리카
- 튀르키예
- 사우디아라비아
- 아랍에미리트
- 기타 중동 및 아프리카
자주 묻는 질문
The global market for Hidradenitis Suppurativa Treatment was estimated to be worth US$ 698 million in 2024 and is forecast to a readjusted size of US$ 927 million by 2031 with a CAGR of 4.2% during the forecast period 2025-2031.
Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin. The exact cause of hidradenitis suppurativa is unknown, but it occurs near hair follicles where there are sweat glands, usually around the groin, bottom, breasts and armpits. There's no cure for HS, but treatments and lifestyle changes can bring some relief and cut down on flare-ups.
The Hidradenitis Suppurativa (HS) treatment market is primarily driven by the increasing awareness and diagnosis rates of this chronic and under-recognized skin condition. As more dermatologists and primary care providers are educated on the early signs of HS, earlier diagnosis and intervention are becoming more common. Additionally, the growing availability of advanced biologic therapies, such as TNF-a inhibitors (e.g., Adalimumab), is transforming HS management from symptomatic relief to targeted disease-modifying treatment. The rise in patient advocacy, increased healthcare access in emerging markets, and continuous investment in dermatological R&D are further fueling market growth.
Despite these advances, the HS treatment market faces several challenges. One of the most significant barriers is the high cost and limited reimbursement of biologic therapies, especially in low- and middle-income countries. Moreover, the limited efficacy of many current treatments for moderate to severe cases and the lack of a definitive cure contribute to patient frustration and discontinuation of therapy. Delayed diagnosis, social stigma, and limited clinical trial data for emerging therapies also restrict broader market expansion and pose ongoing hurdles for pharmaceutical companies and healthcare providers.
The classification of Hidradenitis Suppurativa Treatment includes Medications, Surgery and others, and the proportion of Medications in 2019 is about 76%. Hidradenitis Suppurativa Treatment is widely used in Hospital, Clinical and other field. The most proportion of Hidradenitis Suppurativa Treatment is Hospital, and the proportion in 2024 is 53.53%. Europe is the largest consumption place with a consumption market share of 47.76% in 2024. Following Europe, Asia Pacific is the second largest consumption place with the consumption market share of 23.97%. Market competition is intense. AbbVie, Merck, Pfizer, AstraZeneca, GlaxoSmithKline, etc. are the leaders of the industry.
This report aims to provide a comprehensive presentation of the global market for Hidradenitis Suppurativa Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Hidradenitis Suppurativa Treatment by region & country, by Type, and by Application.
The Hidradenitis Suppurativa Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hidradenitis Suppurativa Treatment.
Market Segmentation
By Company
- AbbVie
- Merck
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Perrigo
- Sun Pharma
- Almirall
- Bausch Health
- Johnson & Johnson
- UCB Pharma
- Amgen
- NCPC
Segment by Type
- Medications
- Surgery
- Others
Segment by Application
- Hospitals
- Clinics
- Others
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Hidradenitis Suppurativa Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Hidradenitis Suppurativa Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Hidradenitis Suppurativa Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Hidradenitis Suppurativa Treatment Product Introduction
- 1.2 Global Hidradenitis Suppurativa Treatment Market Size Forecast (2020-2031)
- 1.3 Hidradenitis Suppurativa Treatment Market Trends & Drivers
- 1.3.1 Hidradenitis Suppurativa Treatment Industry Trends
- 1.3.2 Hidradenitis Suppurativa Treatment Market Drivers & Opportunity
- 1.3.3 Hidradenitis Suppurativa Treatment Market Challenges
- 1.3.4 Hidradenitis Suppurativa Treatment Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Hidradenitis Suppurativa Treatment Players Revenue Ranking (2024)
- 2.2 Global Hidradenitis Suppurativa Treatment Revenue by Company (2020-2025)
- 2.3 Key Companies Hidradenitis Suppurativa Treatment Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Hidradenitis Suppurativa Treatment Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Hidradenitis Suppurativa Treatment
- 2.6 Hidradenitis Suppurativa Treatment Market Competitive Analysis
- 2.6.1 Hidradenitis Suppurativa Treatment Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Hidradenitis Suppurativa Treatment Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hidradenitis Suppurativa Treatment as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 Medications
- 3.1.2 Surgery
- 3.1.3 Others
- 3.2 Global Hidradenitis Suppurativa Treatment Sales Value by Type
- 3.2.1 Global Hidradenitis Suppurativa Treatment Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Hidradenitis Suppurativa Treatment Sales Value, by Type (2020-2031)
- 3.2.3 Global Hidradenitis Suppurativa Treatment Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Hospitals
- 4.1.2 Clinics
- 4.1.3 Others
- 4.2 Global Hidradenitis Suppurativa Treatment Sales Value by Application
- 4.2.1 Global Hidradenitis Suppurativa Treatment Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Hidradenitis Suppurativa Treatment Sales Value, by Application (2020-2031)
- 4.2.3 Global Hidradenitis Suppurativa Treatment Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Hidradenitis Suppurativa Treatment Sales Value by Region
- 5.1.1 Global Hidradenitis Suppurativa Treatment Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Hidradenitis Suppurativa Treatment Sales Value by Region (2020-2025)
- 5.1.3 Global Hidradenitis Suppurativa Treatment Sales Value by Region (2026-2031)
- 5.1.4 Global Hidradenitis Suppurativa Treatment Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
- 5.2.2 North America Hidradenitis Suppurativa Treatment Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
- 5.3.2 Europe Hidradenitis Suppurativa Treatment Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
- 5.4.2 Asia Pacific Hidradenitis Suppurativa Treatment Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
- 5.5.2 South America Hidradenitis Suppurativa Treatment Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Hidradenitis Suppurativa Treatment Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Hidradenitis Suppurativa Treatment Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
- 6.3.2 United States Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Hidradenitis Suppurativa Treatment Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
- 6.4.2 Europe Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Hidradenitis Suppurativa Treatment Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
- 6.5.2 China Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Hidradenitis Suppurativa Treatment Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
- 6.6.2 Japan Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Hidradenitis Suppurativa Treatment Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
- 6.7.2 South Korea Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Hidradenitis Suppurativa Treatment Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
- 6.8.2 Southeast Asia Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Hidradenitis Suppurativa Treatment Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Hidradenitis Suppurativa Treatment Sales Value, 2020-2031
- 6.9.2 India Hidradenitis Suppurativa Treatment Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Hidradenitis Suppurativa Treatment Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 AbbVie
- 7.1.1 AbbVie Profile
- 7.1.2 AbbVie Main Business
- 7.1.3 AbbVie Hidradenitis Suppurativa Treatment Products, Services and Solutions
- 7.1.4 AbbVie Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
- 7.1.5 AbbVie Recent Developments
- 7.2 Merck
- 7.2.1 Merck Profile
- 7.2.2 Merck Main Business
- 7.2.3 Merck Hidradenitis Suppurativa Treatment Products, Services and Solutions
- 7.2.4 Merck Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
- 7.2.5 Merck Recent Developments
- 7.3 Pfizer
- 7.3.1 Pfizer Profile
- 7.3.2 Pfizer Main Business
- 7.3.3 Pfizer Hidradenitis Suppurativa Treatment Products, Services and Solutions
- 7.3.4 Pfizer Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
- 7.3.5 Pfizer Recent Developments
- 7.4 AstraZeneca
- 7.4.1 AstraZeneca Profile
- 7.4.2 AstraZeneca Main Business
- 7.4.3 AstraZeneca Hidradenitis Suppurativa Treatment Products, Services and Solutions
- 7.4.4 AstraZeneca Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
- 7.4.5 AstraZeneca Recent Developments
- 7.5 GlaxoSmithKline
- 7.5.1 GlaxoSmithKline Profile
- 7.5.2 GlaxoSmithKline Main Business
- 7.5.3 GlaxoSmithKline Hidradenitis Suppurativa Treatment Products, Services and Solutions
- 7.5.4 GlaxoSmithKline Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
- 7.5.5 GlaxoSmithKline Recent Developments
- 7.6 Perrigo
- 7.6.1 Perrigo Profile
- 7.6.2 Perrigo Main Business
- 7.6.3 Perrigo Hidradenitis Suppurativa Treatment Products, Services and Solutions
- 7.6.4 Perrigo Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
- 7.6.5 Perrigo Recent Developments
- 7.7 Sun Pharma
- 7.7.1 Sun Pharma Profile
- 7.7.2 Sun Pharma Main Business
- 7.7.3 Sun Pharma Hidradenitis Suppurativa Treatment Products, Services and Solutions
- 7.7.4 Sun Pharma Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
- 7.7.5 Sun Pharma Recent Developments
- 7.8 Almirall
- 7.8.1 Almirall Profile
- 7.8.2 Almirall Main Business
- 7.8.3 Almirall Hidradenitis Suppurativa Treatment Products, Services and Solutions
- 7.8.4 Almirall Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
- 7.8.5 Almirall Recent Developments
- 7.9 Bausch Health
- 7.9.1 Bausch Health Profile
- 7.9.2 Bausch Health Main Business
- 7.9.3 Bausch Health Hidradenitis Suppurativa Treatment Products, Services and Solutions
- 7.9.4 Bausch Health Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
- 7.9.5 Bausch Health Recent Developments
- 7.10 Johnson & Johnson
- 7.10.1 Johnson & Johnson Profile
- 7.10.2 Johnson & Johnson Main Business
- 7.10.3 Johnson & Johnson Hidradenitis Suppurativa Treatment Products, Services and Solutions
- 7.10.4 Johnson & Johnson Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
- 7.10.5 Johnson & Johnson Recent Developments
- 7.11 UCB Pharma
- 7.11.1 UCB Pharma Profile
- 7.11.2 UCB Pharma Main Business
- 7.11.3 UCB Pharma Hidradenitis Suppurativa Treatment Products, Services and Solutions
- 7.11.4 UCB Pharma Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
- 7.11.5 UCB Pharma Recent Developments
- 7.12 Amgen
- 7.12.1 Amgen Profile
- 7.12.2 Amgen Main Business
- 7.12.3 Amgen Hidradenitis Suppurativa Treatment Products, Services and Solutions
- 7.12.4 Amgen Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
- 7.12.5 Amgen Recent Developments
- 7.13 NCPC
- 7.13.1 NCPC Profile
- 7.13.2 NCPC Main Business
- 7.13.3 NCPC Hidradenitis Suppurativa Treatment Products, Services and Solutions
- 7.13.4 NCPC Hidradenitis Suppurativa Treatment Revenue (US$ Million) & (2020-2025)
- 7.13.5 NCPC Recent Developments
8 Industry Chain Analysis
- 8.1 Hidradenitis Suppurativa Treatment Industrial Chain
- 8.2 Hidradenitis Suppurativa Treatment Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Hidradenitis Suppurativa Treatment Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Hidradenitis Suppurativa Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
